Validation of a Lenvatinib Assay: A Pilot Study
Our study describes the successful development of a novel LC-MS/MS assay for quantifying plasma lenvatinib levels. Despite consistent dosing, we observed considerable variability in levels in this group. Further research is required to examine the utility of lenvatinib drug monitoring in the setting of thyroid cancer.
Authors
- Cameron Wood (ORCID: https://orcid.org/0000-0002-9893-3313)
- Eleanor White
- Matti L. Gild (ORCID: https://orcid.org/0000-0002-6670-2254)
- Paul Bonnitcha (ORCID: https://orcid.org/0000-0002-7658-3383)
- Roderick John Clifton-Bligh (ORCID: https://orcid.org/0000-0002-1545-0368)
- Christopher Hodgkins (ORCID: https://orcid.org/0000-0002-0210-6410)
- Lucy Ding
- Bruce G. Robinson
- Monica Majumder (ORCID: https://orcid.org/0000-0002-9796-4687)
Institutions
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Royal North Shore Hospital (AU)
- Cancer Institute of New South Wales (AU)
- North Shore Hospital (NZ)
Publication Details
- Journal
- Endocrine Research
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1080/07435800.2025.2509986
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00